Alteplase Trial Puts ENCHANTED Asian Sites On The Map
This article was originally published in PharmAsia News
Executive Summary
As well as establishing the benefits of lower dosing, new results from a multinational clinical trial with clot-buster alteplase have highlighted the strong performance of Asian study sites, breaking some perceptions in the process.
You may also be interested in...
What Makes Asia Appealing For Clinical Trials?
Asia is continuing to emerge as a global hot spot for clinical trials, helped by positive factors including patient availability and competitive costs, but challenges remain, a recent conference in Seoul heard.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.